This is a no brainer. The news will be great this time next year. Under 7 cents a share? Back up the truck. to Da moon !!!
There are a number of things about Advanced Cell Technologies that can catch an investor's eye. The critical month for ACTC is fast approaching - January 2014, when its Stargardt Syndrome phase II trials are estimated for completion. Stargardt is a disease similar to dry AMD, though its onset is much earlier and is caused by a genetic mutation. ACTC is injecting stem cells into these patients' retinas, and positive results will likely have positive implications for its own dry AMD trials which are a little behind Stargardt in the pipeline, aiming for a July 2014 completion date. The treatments for the two diseases are basically the same thing - injecting stem cells into retinas, so the first half of 2014 will be crucial for Advanced Cell.